|
Quotes & Info
|
| GTXI > SEC Filings for GTXI > Form 8-K on 8-Jan-2013 | All Recent SEC Filings |
8-Jan-2013
Other Events, Financial Statements and Exhibits
On January 8, 2013, GTx, Inc. issued a press release announcing that the U. S. Food and Drug Administration (FDA) has designated enobosarm (GTx-024) for the prevention and treatment of muscle wasting in patients with non-small cell lung cancer as a Fast Track development program, a copy of which is furnished as Exhibit 99.1 to this Current Report.
(d) Exhibits
Exhibit Number Description 99.1 Press Release issued by GTx, Inc. dated January 8, 2013 |
|
|